Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclophosphamide, Doxorubicin, Etoposide vs Carboplatin, Paclitaxel in Extensive Stage SCLC
NCT00003696Phase 3Unknown
- Sponsor
- Commissie voor Klinisch Toegepast Onderzoek
- Start
- Oct 1998
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of carboplatin, cyclophosphamide, doxorubicin, etoposide, paclitaxel in small cell lung cancer (SCLC), sponsored by Commissie voor Klinisch Toegepast Onderzoek. Status: unknown.
02
Drugs
carboplatincyclophosphamidedoxorubicinetoposidepaclitaxel
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00003696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003696.